Profluent, an AI-first protein design company backed by Jeff Bezos, announced a multi-program partnership with Eli Lilly worth up to $2.25 billion to develop AI-designed enzymes for genetic medicines1
The collaboration aims to develop more precise and scalable DNA-editing tools by combining Profluent's AI protein design models with Lilly's expertise in genetic medicines1
Profluent will design recombinases for specific genetic targets, while Lilly will have exclusive rights to develop and commercialize selected candidates1
The deal structure includes an upfront payment, potential development and commercial milestone payments, and tiered royalties on net sales1
Sources:
1. https://www.finanznachrichten.de/nachrichten-2026-04/68327184-profluent-inks-up-to-dollar-2-25-bln-deal-with-lilly-for-genetic-medicines-020.htm